Dianthus Therapeutics, Inc. /DE/ — Director's Dealing 2021

Oct 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Magenta Therapeutics, Inc. (MGTA)
CIK: 0001690585
Period of Report: 2021-10-01

Reporting Person: Humphrey Jeffrey (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-01	Stock Option (Right to Buy)	$7.51	A	275000	Acquired	2031-09-30	Common Stock (275000)	Direct

Footnotes

F1: This option shall vest and become exerciseable over four years, with 25% of this option vesting on October 1, 2022, and the remainder vesting in 36 equal monthly installments thereafter.